Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report
Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000543251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850274652188835840 |
|---|---|
| author | Ryota Tatsuhige Keiki Yokoo Taku Hatakeyama Takayuki Nagao Satoshi Ota Gen Yamada Hirofumi Chiba |
| author_facet | Ryota Tatsuhige Keiki Yokoo Taku Hatakeyama Takayuki Nagao Satoshi Ota Gen Yamada Hirofumi Chiba |
| author_sort | Ryota Tatsuhige |
| collection | DOAJ |
| description |
Introduction:
Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III NSCLC. The efficacy and safety of sequential treatment in patients with METex14 are unclear. Reports have suggested that the administration of tyrosine kinase inhibitors after ICIs could potentially increase the incidence of drug-induced lung injury.
Case Presentation:
A 76-year-old female patient was diagnosed NSCLC harbouring METex14 with clinical stage IIIA (cT2aN2M0). Chemoradiotherapy and consolidation therapy with durvalumab were initiated to achieve a cure. Durvalumab was discontinued due to interstitial lung disease (ILD). After systemic disease progression was observed, tepotinib was initiated 7 weeks after the last dose of durvalumab. She developed ILD due to the sequential treatment of tepotinib after durvalumab.
Conclusion:
It is unclear whether tepotinib is safe in patients with METex14 after durvalumab administration. Considering the residual period of ICIs in the body, caution should be exercised when initiating molecular-targeted drugs after ICI administration in patients with NSCLC with METex14.
|
| format | Article |
| id | doaj-art-9d29d00a368145a7b65dc6cd96802740 |
| institution | OA Journals |
| issn | 1662-6575 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj-art-9d29d00a368145a7b65dc6cd968027402025-08-20T01:51:04ZengKarger PublishersCase Reports in Oncology1662-65752025-01-0118114415010.1159/000543251Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case ReportRyota TatsuhigeKeiki YokooTaku HatakeyamaTakayuki NagaoSatoshi OtaGen YamadaHirofumi Chiba Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14). Whereas durvalumab is an immune-checkpoint inhibitor (ICI), which has been administered to those with unresectable stage III NSCLC. The efficacy and safety of sequential treatment in patients with METex14 are unclear. Reports have suggested that the administration of tyrosine kinase inhibitors after ICIs could potentially increase the incidence of drug-induced lung injury. Case Presentation: A 76-year-old female patient was diagnosed NSCLC harbouring METex14 with clinical stage IIIA (cT2aN2M0). Chemoradiotherapy and consolidation therapy with durvalumab were initiated to achieve a cure. Durvalumab was discontinued due to interstitial lung disease (ILD). After systemic disease progression was observed, tepotinib was initiated 7 weeks after the last dose of durvalumab. She developed ILD due to the sequential treatment of tepotinib after durvalumab. Conclusion: It is unclear whether tepotinib is safe in patients with METex14 after durvalumab administration. Considering the residual period of ICIs in the body, caution should be exercised when initiating molecular-targeted drugs after ICI administration in patients with NSCLC with METex14. https://karger.com/article/doi/10.1159/000543251 |
| spellingShingle | Ryota Tatsuhige Keiki Yokoo Taku Hatakeyama Takayuki Nagao Satoshi Ota Gen Yamada Hirofumi Chiba Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report Case Reports in Oncology |
| title | Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report |
| title_full | Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report |
| title_fullStr | Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report |
| title_full_unstemmed | Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report |
| title_short | Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report |
| title_sort | interstitial lung disease due to tepotinib after durvalumab in a patient with lung adenocarcinoma harbouring met exon 14 skipping mutation a case report |
| url | https://karger.com/article/doi/10.1159/000543251 |
| work_keys_str_mv | AT ryotatatsuhige interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT keikiyokoo interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT takuhatakeyama interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT takayukinagao interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT satoshiota interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT genyamada interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport AT hirofumichiba interstitiallungdiseaseduetotepotinibafterdurvalumabinapatientwithlungadenocarcinomaharbouringmetexon14skippingmutationacasereport |